Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Lenvatinib in Locally Advanced Invasive Thyroid Cancer
NCT04321954Phase 2Completed
- Sponsor
- Massachusetts Eye and Ear
- Start
- Mar 2021
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in differentiated thyroid cancer (DTC), sponsored by Massachusetts Eye and Ear. Primary endpoint: Overall R0/R1 resection rate at 112 days. Started Mar 2021; status: completed.
02
Drugs
lenvatinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT04321954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04321954.